Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11559279 | 0.93 | LMNA (0.40) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL6805970 | 0.90 | NOS2 (0.33) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL7374027 | 0.90 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL7379328 | 0.90 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL11475872 | 0.90 | PRCP (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL11474555 | 0.90 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL599792 | 0.90 | ALDH1A1 (0.45) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL11618241 | 0.89 | PRCP (0.38) | PRCPDPP4DPP8DPP7SCN4A | |
| SCHEMBL8518994 | 0.88 | LMNA (0.42) | NOS2NOS3NOS1PRCPELANE | |
| SCHEMBL30265157 | 0.87 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891771-A1 | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases | Health Now, Inc. (US) | 1999-01-20 | — | — | EP | claimed |
| CN-102573845-A | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof | SHIRE LLC | 2012-07-11 | — | — | CN | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-0891771-A1 | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases | Health Now, Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | NOS2 841/4885NOS3 746/4885NOS1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.